The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Genetic Virus Vector-Global Market Insights and Sales Trends 2024
Synopsis
The global Genetic Virus Vector market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Genetic Virus Vector in various end use industries. The expanding demands from the Gene Therapy and Vaccinology, are propelling Genetic Virus Vector market. Retroviral Vectors, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Adenoviral Vectors segment is estimated at % CAGR for the next seven-year period.
Asia Pacific shows high growth potential for Genetic Virus Vector market, driven by demand from China, the second largest economy with some signs of stabilising, the Genetic Virus Vector market in China is forecast to reach US$ million by 2029, trailing a CAGR of % over the 2023-2029 period, while the U.S. market will reach US$ million by 2029, exhibiting a CAGR of % during the same period.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Genetic Virus Vector, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Genetic Virus Vector market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Genetic Virus Vector market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Genetic Virus Vector sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Genetic Virus Vector covered in this report include FUJIFILM Diosynth Biotechnologies U.S.A., Sanofi, Lonza, Merck KGaA, GENERAL ELECTRIC COMPANY, Oxford BioMedica, Spark Therapeutics, Inc., uniQure N.V. and FinVector Vision Therapies, etc.
The global Genetic Virus Vector market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
FUJIFILM Diosynth Biotechnologies U.S.A.
Sanofi
Lonza
Merck KGaA
GENERAL ELECTRIC COMPANY
Oxford BioMedica
Spark Therapeutics, Inc.
uniQure N.V.
FinVector Vision Therapies
Brammer Bio
Cell and Gene Therapy Catapult
Cobra Biologics
REGENXBIO Inc.
Kaneka Eurogentec S.A.
Global Genetic Virus Vector market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Genetic Virus Vector market, Segment by Type:
Retroviral Vectors
Adenoviral Vectors
Adeno-Associated Viral Vectors
Other
Global Genetic Virus Vector market, by Application
Gene Therapy
Vaccinology
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Genetic Virus Vector companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
The global Genetic Virus Vector market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Genetic Virus Vector in various end use industries. The expanding demands from the Gene Therapy and Vaccinology, are propelling Genetic Virus Vector market. Retroviral Vectors, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Adenoviral Vectors segment is estimated at % CAGR for the next seven-year period.
Asia Pacific shows high growth potential for Genetic Virus Vector market, driven by demand from China, the second largest economy with some signs of stabilising, the Genetic Virus Vector market in China is forecast to reach US$ million by 2029, trailing a CAGR of % over the 2023-2029 period, while the U.S. market will reach US$ million by 2029, exhibiting a CAGR of % during the same period.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Genetic Virus Vector, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Genetic Virus Vector market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Genetic Virus Vector market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Genetic Virus Vector sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Genetic Virus Vector covered in this report include FUJIFILM Diosynth Biotechnologies U.S.A., Sanofi, Lonza, Merck KGaA, GENERAL ELECTRIC COMPANY, Oxford BioMedica, Spark Therapeutics, Inc., uniQure N.V. and FinVector Vision Therapies, etc.
The global Genetic Virus Vector market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
FUJIFILM Diosynth Biotechnologies U.S.A.
Sanofi
Lonza
Merck KGaA
GENERAL ELECTRIC COMPANY
Oxford BioMedica
Spark Therapeutics, Inc.
uniQure N.V.
FinVector Vision Therapies
Brammer Bio
Cell and Gene Therapy Catapult
Cobra Biologics
REGENXBIO Inc.
Kaneka Eurogentec S.A.
Global Genetic Virus Vector market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Genetic Virus Vector market, Segment by Type:
Retroviral Vectors
Adenoviral Vectors
Adeno-Associated Viral Vectors
Other
Global Genetic Virus Vector market, by Application
Gene Therapy
Vaccinology
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Genetic Virus Vector companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Index1 Market Overview of Genetic Virus Vector
1.1 Genetic Virus Vector Market Overview
1.1.1 Genetic Virus Vector Product Scope
1.1.2 Genetic Virus Vector Market Status and Outlook
1.2 Global Genetic Virus Vector Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global Genetic Virus Vector Market Size by Region (2018-2029)
1.4 Global Genetic Virus Vector Historic Market Size by Region (2018-2023)
1.5 Global Genetic Virus Vector Market Size Forecast by Region (2024-2029)
1.6 Key Regions, Genetic Virus Vector Market Size (2018-2029)
1.6.1 North America Genetic Virus Vector Market Size (2018-2029)
1.6.2 Europe Genetic Virus Vector Market Size (2018-2029)
1.6.3 Asia-Pacific Genetic Virus Vector Market Size (2018-2029)
1.6.4 Latin America Genetic Virus Vector Market Size (2018-2029)
1.6.5 Middle East & Africa Genetic Virus Vector Market Size (2018-2029)
2 Genetic Virus Vector Market by Type
2.1 Introduction
2.1.1 Retroviral Vectors
2.1.2 Adenoviral Vectors
2.1.3 Adeno-Associated Viral Vectors
2.1.4 Other
2.2 Global Genetic Virus Vector Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global Genetic Virus Vector Historic Market Size by Type (2018-2023)
2.2.2 Global Genetic Virus Vector Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America Genetic Virus Vector Revenue Breakdown by Type (2018-2029)
2.3.2 Europe Genetic Virus Vector Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific Genetic Virus Vector Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America Genetic Virus Vector Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa Genetic Virus Vector Revenue Breakdown by Type (2018-2029)
3 Genetic Virus Vector Market Overview by Application
3.1 Introduction
3.1.1 Gene Therapy
3.1.2 Vaccinology
3.2 Global Genetic Virus Vector Market Size by Application: 2018 VS 2022 VS 2029
3.2.1 Global Genetic Virus Vector Historic Market Size by Application (2018-2023)
3.2.2 Global Genetic Virus Vector Forecasted Market Size by Application (2024-2029)
3.3 Key Regions Market Size by Application
3.3.1 North America Genetic Virus Vector Revenue Breakdown by Application (2018-2029)
3.3.2 Europe Genetic Virus Vector Revenue Breakdown by Application (2018-2029)
3.3.3 Asia-Pacific Genetic Virus Vector Revenue Breakdown by Application (2018-2029)
3.3.4 Latin America Genetic Virus Vector Revenue Breakdown by Application (2018-2029)
3.3.5 Middle East and Africa Genetic Virus Vector Revenue Breakdown by Application (2018-2029)
4 Genetic Virus Vector Competition Analysis by Players
4.1 Global Genetic Virus Vector Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Genetic Virus Vector as of 2022)
4.3 Date of Key Players Enter into Genetic Virus Vector Market
4.4 Global Top Players Genetic Virus Vector Headquarters and Area Served
4.5 Key Players Genetic Virus Vector Product Solution and Service
4.6 Competitive Status
4.6.1 Genetic Virus Vector Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 FUJIFILM Diosynth Biotechnologies U.S.A.
5.1.1 FUJIFILM Diosynth Biotechnologies U.S.A. Profile
5.1.2 FUJIFILM Diosynth Biotechnologies U.S.A. Main Business
5.1.3 FUJIFILM Diosynth Biotechnologies U.S.A. Genetic Virus Vector Products, Services and Solutions
5.1.4 FUJIFILM Diosynth Biotechnologies U.S.A. Genetic Virus Vector Revenue (US$ Million) & (2018-2023)
5.1.5 FUJIFILM Diosynth Biotechnologies U.S.A. Recent Developments
5.2 Sanofi
5.2.1 Sanofi Profile
5.2.2 Sanofi Main Business
5.2.3 Sanofi Genetic Virus Vector Products, Services and Solutions
5.2.4 Sanofi Genetic Virus Vector Revenue (US$ Million) & (2018-2023)
5.2.5 Sanofi Recent Developments
5.3 Lonza
5.3.1 Lonza Profile
5.3.2 Lonza Main Business
5.3.3 Lonza Genetic Virus Vector Products, Services and Solutions
5.3.4 Lonza Genetic Virus Vector Revenue (US$ Million) & (2018-2023)
5.3.5 Merck KGaA Recent Developments
5.4 Merck KGaA
5.4.1 Merck KGaA Profile
5.4.2 Merck KGaA Main Business
5.4.3 Merck KGaA Genetic Virus Vector Products, Services and Solutions
5.4.4 Merck KGaA Genetic Virus Vector Revenue (US$ Million) & (2018-2023)
5.4.5 Merck KGaA Recent Developments
5.5 GENERAL ELECTRIC COMPANY
5.5.1 GENERAL ELECTRIC COMPANY Profile
5.5.2 GENERAL ELECTRIC COMPANY Main Business
5.5.3 GENERAL ELECTRIC COMPANY Genetic Virus Vector Products, Services and Solutions
5.5.4 GENERAL ELECTRIC COMPANY Genetic Virus Vector Revenue (US$ Million) & (2018-2023)
5.5.5 GENERAL ELECTRIC COMPANY Recent Developments
5.6 Oxford BioMedica
5.6.1 Oxford BioMedica Profile
5.6.2 Oxford BioMedica Main Business
5.6.3 Oxford BioMedica Genetic Virus Vector Products, Services and Solutions
5.6.4 Oxford BioMedica Genetic Virus Vector Revenue (US$ Million) & (2018-2023)
5.6.5 Oxford BioMedica Recent Developments
5.7 Spark Therapeutics, Inc.
5.7.1 Spark Therapeutics, Inc. Profile
5.7.2 Spark Therapeutics, Inc. Main Business
5.7.3 Spark Therapeutics, Inc. Genetic Virus Vector Products, Services and Solutions
5.7.4 Spark Therapeutics, Inc. Genetic Virus Vector Revenue (US$ Million) & (2018-2023)
5.7.5 Spark Therapeutics, Inc. Recent Developments
5.8 uniQure N.V.
5.8.1 uniQure N.V. Profile
5.8.2 uniQure N.V. Main Business
5.8.3 uniQure N.V. Genetic Virus Vector Products, Services and Solutions
5.8.4 uniQure N.V. Genetic Virus Vector Revenue (US$ Million) & (2018-2023)
5.8.5 uniQure N.V. Recent Developments
5.9 FinVector Vision Therapies
5.9.1 FinVector Vision Therapies Profile
5.9.2 FinVector Vision Therapies Main Business
5.9.3 FinVector Vision Therapies Genetic Virus Vector Products, Services and Solutions
5.9.4 FinVector Vision Therapies Genetic Virus Vector Revenue (US$ Million) & (2018-2023)
5.9.5 FinVector Vision Therapies Recent Developments
5.10 Brammer Bio
5.10.1 Brammer Bio Profile
5.10.2 Brammer Bio Main Business
5.10.3 Brammer Bio Genetic Virus Vector Products, Services and Solutions
5.10.4 Brammer Bio Genetic Virus Vector Revenue (US$ Million) & (2018-2023)
5.10.5 Brammer Bio Recent Developments
5.11 Cell and Gene Therapy Catapult
5.11.1 Cell and Gene Therapy Catapult Profile
5.11.2 Cell and Gene Therapy Catapult Main Business
5.11.3 Cell and Gene Therapy Catapult Genetic Virus Vector Products, Services and Solutions
5.11.4 Cell and Gene Therapy Catapult Genetic Virus Vector Revenue (US$ Million) & (2018-2023)
5.11.5 Cell and Gene Therapy Catapult Recent Developments
5.12 Cobra Biologics
5.12.1 Cobra Biologics Profile
5.12.2 Cobra Biologics Main Business
5.12.3 Cobra Biologics Genetic Virus Vector Products, Services and Solutions
5.12.4 Cobra Biologics Genetic Virus Vector Revenue (US$ Million) & (2018-2023)
5.12.5 Cobra Biologics Recent Developments
5.13 REGENXBIO Inc.
5.13.1 REGENXBIO Inc. Profile
5.13.2 REGENXBIO Inc. Main Business
5.13.3 REGENXBIO Inc. Genetic Virus Vector Products, Services and Solutions
5.13.4 REGENXBIO Inc. Genetic Virus Vector Revenue (US$ Million) & (2018-2023)
5.13.5 REGENXBIO Inc. Recent Developments
5.14 Kaneka Eurogentec S.A.
5.14.1 Kaneka Eurogentec S.A. Profile
5.14.2 Kaneka Eurogentec S.A. Main Business
5.14.3 Kaneka Eurogentec S.A. Genetic Virus Vector Products, Services and Solutions
5.14.4 Kaneka Eurogentec S.A. Genetic Virus Vector Revenue (US$ Million) & (2018-2023)
5.14.5 Kaneka Eurogentec S.A. Recent Developments
6 North America
6.1 North America Genetic Virus Vector Market Size by Country (2018-2029)
6.2 United States
6.3 Canada
7 Europe
7.1 Europe Genetic Virus Vector Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Genetic Virus Vector Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Genetic Virus Vector Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Genetic Virus Vector Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Genetic Virus Vector Market Dynamics
11.1 Genetic Virus Vector Industry Trends
11.2 Genetic Virus Vector Market Drivers
11.3 Genetic Virus Vector Market Challenges
11.4 Genetic Virus Vector Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
